GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

Reported fourth quarter 2023 revenue from continuing operations1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross margins2 from continuing operations to 56% Narrowed fourth quarter 2023 adjusted net loss2 to$ 17.8M and delivered 51% year-over-year cash burn reduction Issued guidance to deliver between $220M and$ 230M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ...